GlassScriptPhysician profile
Jennifer Becerra
NPI 1184377574
$4,020.44
in general payments reported to CMS, 2019-2025
21 companies · $904 in 2025
The $904 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $539 · 2023: $1,357 · 2024: $1,220 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,481.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $1,281.77 | 2022-2025 | Uptravi, Opsumit |
| E.R. Squibb & Sons, L.L.C. | $469.16 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $283.12 | 2022-2025 | Farxiga, Lokelma |
| Pfizer INC. | $275.50 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $255.91 | 2022-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $218.81 | 2022-2023 | Lifevest |
| Merck Sharp & Dohme LLC | $202.58 | 2022-2025 | Verquvo |
| Sanofi-Aventis U.S. LLC | $176.47 | 2022-2024 | |
| Edwards Lifesciences Corporation | $161.16 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.22 | 2022-2025 | Jardiance |
| Medtronic, INC. | $113.18 | 2023 | Corevalve Evolut R |
| Amgen INC. | $97.35 | 2022-2025 | Repatha |
| Novo Nordisk INC | $92.14 | 2024-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $57.30 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $41.71 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $40.34 | 2023-2025 | Wavewriter Alpha Prime 16, Lux-Dx Insertable Cardiac Monitor |
| Scpharmaceuticals INC. | $33.02 | 2024 | |
| Kiniksa Pharmaceuticals, LTD. | $24.40 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $23.54 | 2023 | Inpefa |
| Azurity Pharmaceuticals, INC. | $14.72 | 2025 | Edarbi |
| Amarin Pharma, INC. | $13.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Becerra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.